Medicus Pharma Ltd. (MDCX)
NASDAQ: MDCX · Real-Time Price · USD
5.85
+0.35 (6.36%)
May 14, 2025, 9:39 AM - Market open
Company Description
Medicus Pharma Ltd., a biotech/life sciences company, focused on accelerating the clinical development programs of novel and disruptive therapeutic assets.
The company is developing SkinJect, with an indication for basal cell carcinoma that is drug device combination product using novel dissolvable microneedle arrays for the treatment of non-melanoma skin cancers.
Medicus Pharma Ltd. was founded in 2015 and is headquartered in Toronto, Canada.
Medicus Pharma Ltd.
| Country | Canada |
| Founded | 2008 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| CEO | Raza Bokhari |
Contact Details
Address: One First Canadian Place, Suite 3400 Toronto, ON M5X 1A4 Canada | |
| Phone | 610-636-0184 |
| Website | medicuspharma.com |
Stock Details
| Ticker Symbol | MDCX |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001997296 |
| ISIN Number | CA58471K2020 |
| Employer ID | 98-1778211 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raza Bokhari M.B.A., M.D., MBA | Chief Executive Officer and Executive Chairman |
| Dr. Edward J. Brennan Jr., F.A.C.S., FACS, M.D. | Chief Scientific Officer and Head of Research & Development Program |
| Carolyn Bonner | President |
| Maryann Adesso | Chief of Staff |
| Dr. Faisal Mehmud M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| May 13, 2025 | 424B3 | Prospectus |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 5, 2025 | 424B3 | Prospectus |
| May 5, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| May 5, 2025 | 8-K | Current Report |
| Apr 30, 2025 | 10-K/A | [Amend] Annual report |
| Apr 28, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| Apr 28, 2025 | 424B3 | Prospectus |
| Apr 28, 2025 | 8-K | Current Report |